Atopic Dermatitis - Epidemiology Analysis and Forecast, 2020-2030

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Although the condition affects people of all ages, it is primarily common among infants and children (Bowcock and Cookson, 2004). In general, the prevalence of AD is increasing worldwide, with high prevalence in Western and developed nations compared with other parts of the world. However, recent trends demonstrate a gradual rise in prevalence in developing countries and plateauing prevalence in developed countries (Asher et al., 2006). Although AD is not life-threatening, it has a huge impact on the patient’s quality of life and causes a significant economic burden (Carroll et al., 2005).



The publisher's epidemiologists utilized nationally representative and country-specific peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the 12-month diagnosed prevalent cases of AD. For the 7MM, diagnosed prevalent cases of AD were segmented by age, sex, and severity.

The publisher's epidemiologists forecast that the 12-month diagnosed prevalent cases of AD in the 7MM will grow by an annual growth rate (AGR) of 0.03% over the next 10 years, from 42,138,193 cases in 2020 to 42,245,459 cases in 2030. Trends in the 7MM and specific markets can be attributed in part to changes in the underlying population structure. As atopic dermatitis is most frequently diagnosed in children and adolescents, the condition inflicts considerable psychosocial and economic burden on the families of the affected. More research is needed to understand the etiological factors associated with AD to take preventive measures and reduce these burdens.

Scope

• The Atopic Dermatitis Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Atopic Dermatitis (AD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report includes a 10-year epidemiological forecast for the 12-month diagnosed prevalent cases of AD segmented by age (0-11, 12-17, 18-29 years, and by 10-year age groups up to 80 years and older), sex, and severity (mild, moderate, and severe). The epidemiology model accompanying this report also includes diagnosed prevalent cases of AD severity segmented by pediatric and adult population and total prevalent cases for all ages and both sexes combined
• The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM

Reasons to Buy

The AD Epidemiology series will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global AD markets
• Quantify patient populations in the global AD markets to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered
• Understand magnitude of the AD population by age, sex, and severity